Visceral Fat vs. Subcutaneous Fat: Why Location Changes Metabolic Risk

This article is part of our Body Composition & Muscle Longevity Guide, which examines muscle, visceral fat, fat distribution, DEXA, and metabolic health in the context of healthy aging.

What Is Subcutaneous Fat?

Subcutaneous adipose tissue is the fat stored directly beneath the skin. It is the soft tissue that can usually be pinched at the abdomen, hips, thighs, arms, and other parts of the body.

Most human body fat is stored in this compartment.

Subcutaneous adipose tissue provides long-term energy storage, insulation, cushioning, and endocrine functions. Like other adipose tissue, it is biologically active and communicates with the rest of the body through hormones, fatty acids, immune signals, and other molecules.

Its metabolic behavior varies substantially according to location.

Fat stored around the hips and thighs, often called gluteofemoral fat, has repeatedly been associated with a more favorable glucose and lipid profile when compared with abdominal fat. This lower-body depot tends to store fatty acids for longer periods and may provide a relatively stable reservoir for excess energy.

Subcutaneous abdominal fat is not necessarily equivalent. Larger amounts of abdominal subcutaneous adiposity commonly accompany obesity and metabolic dysfunction, and deeper abdominal subcutaneous compartments may have less favorable characteristics than lower-body fat.

It is therefore more accurate to think of subcutaneous fat as a collection of regional fat depots rather than one uniform tissue.

What Is Visceral Fat?

Visceral adipose tissue is located inside the abdominal cavity rather than beneath the skin. Important visceral depots include fat associated with the omentum and mesentery surrounding the abdominal organs and intestines.

A certain amount of visceral fat is normal. The clinical concern is excessive accumulation.

Visceral adipocytes differ from many subcutaneous adipocytes in several ways. They tend to be more responsive to signals that promote the release of stored fatty acids, demonstrate greater insulin resistance, and can develop an inflammatory immune environment as visceral obesity progresses.

This helps explain why two people with similar total body-fat percentages can have very different metabolic profiles.

A person who stores a relatively large proportion of excess energy within the visceral abdomen is generally at greater cardiometabolic risk than someone whose fat is stored predominantly in metabolically healthier subcutaneous depots.

For the connection with glucose regulation, see Visceral Fat and Insulin Resistance.

Why Visceral Fat Is More Closely Linked to Metabolic Disease

Visceral fat is strongly associated with insulin resistance, type 2 diabetes, hypertension, abnormal lipid patterns, fatty liver disease, and cardiovascular disease. Several mechanisms probably contribute rather than one pathway explaining the entire relationship.

Higher Fatty-Acid Release

Visceral adipose tissue is relatively sensitive to lipolysis, the process by which stored triglycerides are broken down and fatty acids are released.

Some visceral depots drain through the portal circulation, which carries blood directly toward the liver. Greater fatty-acid delivery to the liver may contribute to hepatic insulin resistance, increased triglyceride production, and accumulation of liver fat.

Inflammatory Signaling

As visceral fat expands, its cellular environment can change. Enlarged adipocytes, immune-cell infiltration, altered adipokine secretion, local hypoxia, and inflammatory signaling have all been described in dysfunctional visceral adipose tissue.

This does not mean that visceral fat simply releases a single inflammatory substance that causes metabolic disease. The relationship involves adipose tissue, liver, skeletal muscle, immune signaling, energy balance, genetics, and multiple endocrine pathways.

Insulin Resistance

Visceral adiposity frequently accompanies reduced insulin sensitivity. As insulin becomes less effective, the pancreas may compensate by producing more insulin in order to maintain normal glucose levels.

This is one reason metabolic dysfunction can develop well before fasting glucose crosses into the diabetic range.

For the larger metabolic picture, see our Metabolic Health & Insulin Resistance Longevity Guide.

Why Subcutaneous Fat Can Behave Differently

Adipose tissue has to store excess energy somewhere.

A healthy subcutaneous fat depot can expand by increasing the size and, in some circumstances, the number of adipocytes available to store triglycerides. This allows excess fatty acids to remain in adipose tissue rather than spilling into organs that are poorly equipped for long-term fat storage.

Lower-body subcutaneous fat appears particularly effective at this job.

Population studies have repeatedly associated greater gluteofemoral fat with lower cardiometabolic risk after accounting for total adiposity. Researchers have proposed several explanations, including slower lipid turnover, longer-term fatty-acid storage, differences in adipokine signaling, and a greater capacity for healthy adipose expansion.

This does not make unlimited subcutaneous fat desirable or suggest that obesity is metabolically harmless when visceral fat is low.

It does show why total body-fat percentage cannot tell us everything about metabolic health.

Someone with 30% body fat stored predominantly in the hips, thighs, and subcutaneous tissue may have a very different metabolic profile from someone with the same total percentage but substantially more visceral and liver fat.

The Next Question Is Where Fat Goes When Storage Capacity Is Exceeded

Visceral fat is only one part of the fat-distribution story.

Fat can also accumulate in tissues that are not primarily designed for long-term energy storage. This is often described as ectopic fat.

Clinically important examples include:

• fat within the liver
• fat within and around skeletal muscle
• fat surrounding the heart
• fat around blood vessels
• fat involving the pancreas and other organs

Liver fat is particularly closely connected with insulin resistance and metabolic dysfunction. Visceral adiposity and liver fat commonly occur together, although they are not the same measurement.

This has led to a broader view of obesity and metabolic disease in which the quality and distribution of adipose tissue can be as important as total fat mass.

A person may therefore have a relatively modest BMI but substantial visceral or ectopic fat. Conversely, someone with a higher BMI may have a considerable amount of metabolically less harmful subcutaneous fat and comparatively little visceral fat.

Neither BMI nor appearance can reliably determine this on its own.

Age, Sex Hormones, and Fat Distribution

Body-fat distribution changes over the lifespan and differs between women and men.

Before menopause, women generally store a greater proportion of fat in subcutaneous depots, particularly around the hips and thighs. Men tend to carry a larger proportion of fat within the abdominal and visceral compartments.

The menopausal transition can alter that pattern.

Declining ovarian estrogen occurs alongside a relative shift toward greater abdominal and visceral adiposity. Aging, physical activity, diet, sleep, energy balance, genetics, and other hormonal changes are also involved, so the change should not be attributed entirely to estrogen.

Recent reviews continue to find an increase in visceral adiposity around menopause, while also emphasizing that separating the effects of menopause itself from chronological aging and lifestyle is difficult.

This is one reason body composition may change substantially during midlife even when the scale moves relatively little.

How Is Visceral Fat Measured?

Visceral fat cannot be assessed reliably by simply looking at someone's abdomen.

Waist circumference is a useful and inexpensive clinical marker of central adiposity, but it does not directly separate visceral fat from abdominal subcutaneous fat.

Imaging provides more detail.

CT and MRI

Computed tomography and MRI can directly visualize abdominal adipose tissue and distinguish visceral from subcutaneous compartments. They are widely used as reference methods in research and selected clinical settings.

Routine CT is generally not performed solely to measure visceral fat because it involves substantially more radiation than DEXA. MRI avoids ionizing radiation but is more expensive and less practical for routine serial body-composition tracking.

DEXA

Modern whole-body DEXA systems can estimate visceral adipose tissue within the abdominal region while also measuring total fat, regional fat, lean soft tissue, and bone.

DEXA does not produce the same direct anatomical measurement as CT or MRI, but it provides a practical way to follow visceral adiposity alongside the rest of body composition.

At HormoneSynergy®, Hologic® DEXA body composition testing includes assessment of visceral fat as well as lean tissue, total and regional body fat, and bone.

For more detail, see DEXA Body Composition Scan: What It Measures and Why It Matters.

Can Visceral Fat Be Reduced?

Yes. Visceral adipose tissue responds to changes in energy balance, physical activity, and weight loss.

The appropriate strategy depends on the person, but commonly includes nutrition that produces a sustainable reduction in excess energy intake when weight loss is needed, regular aerobic activity, resistance training, adequate protein, sleep, and treatment of medical factors contributing to metabolic dysfunction.

Resistance training deserves particular attention because reducing fat while losing unnecessary muscle is a poor trade. Maintaining or improving muscle helps preserve physical function and provides a large metabolically active tissue for glucose disposal.

Some patients with obesity or significant metabolic disease may also benefit from physician-guided pharmacologic treatment. The purpose of treatment is not simply to make the scale move. Changes in visceral fat, muscle, glucose regulation, liver health, cardiovascular risk, and overall physical function are more informative.

Serial body-composition measurements can help determine whether those changes are actually occurring.

Visceral Fat, Muscle, and Healthy Aging

Body composition changes with age in more than one direction.

Visceral fat may increase while skeletal muscle and strength decline. When excess adiposity occurs together with impaired muscle mass or function, the pattern may meet criteria for sarcopenic obesity.

This combination can be missed by body weight alone. Someone can remain at roughly the same weight while gradually replacing lean tissue with fat and moving a larger proportion of that fat into the abdomen.

The practical approach is to follow the compartments that matter and preserve physical function while metabolic risk is being addressed.

Our Body Composition & Muscle Longevity Guide brings these measurements together with muscle strength, DEXA, sarcopenia, resistance training, and healthy aging.

Frequently Asked Questions

Which is more metabolically harmful, visceral fat or subcutaneous fat?

Excess visceral fat is more consistently associated with insulin resistance, fatty liver disease, type 2 diabetes, and cardiovascular risk. Subcutaneous fat varies by location, and lower-body gluteofemoral fat may have a relatively favorable metabolic profile.

Is subcutaneous fat healthy?

Subcutaneous fat performs normal physiological functions and provides an important storage site for excess energy. It should not simply be classified as healthy or unhealthy. Its location, amount, cellular health, and the presence of visceral or ectopic fat all influence metabolic risk.

Why is visceral fat associated with insulin resistance?

Visceral adipose tissue has relatively high lipolytic activity and can contribute to increased fatty-acid delivery, altered adipokine signaling, inflammation, liver fat accumulation, and impaired insulin signaling. These mechanisms interact rather than acting independently.

Can a thin person have high visceral fat?

Yes. BMI and outward appearance do not directly measure fat distribution. Some people with normal body weight carry relatively high amounts of visceral or ectopic fat. The informal term TOFI, or “thin outside, fat inside,” is sometimes used in research discussions, but it is not a formal medical diagnosis.

Does menopause increase visceral fat?

The menopausal transition is commonly accompanied by a shift toward greater abdominal and visceral adiposity. Declining estrogen is one contributor, although aging, activity, diet, sleep, genetics, and overall energy balance also influence the change.

Can DEXA measure visceral fat?

Modern whole-body DEXA systems can estimate visceral adipose tissue within the abdominal region. CT and MRI provide more direct anatomical measurements, while DEXA offers a practical method for following visceral fat alongside total fat, lean tissue, and bone.

Does losing weight reduce visceral fat?

Visceral fat generally decreases with effective weight loss and regular physical activity. The goal should also include preserving muscle through resistance training, adequate protein, and appropriate nutrition.

Is waist circumference useful if I cannot get a DEXA scan?

Yes. Waist circumference is a useful clinical marker of central adiposity and cardiometabolic risk. It cannot distinguish visceral from subcutaneous abdominal fat, but it is inexpensive and can be useful for following changes over time.

Clinical References

• Shetty S, et al. Visceral Adiposity and Cardiometabolic Risk: Clinical Insights and Assessment. Cardiology in Review. 2025.
• Role of Systemic and Epicardial Adipose Tissue in Cardiometabolic Disease. Nature Reviews Cardiology. 2026.
• Alser M, et al. Mechanisms of Body Fat Distribution and Gluteal-Femoral Fat Protection Against Metabolic Disorders. Frontiers in Nutrition. 2024.
• Health of Adipose Tissue: Oestrogen Matters. 2025.
• Menopause and Body Composition: A Complex Field. 2025.
• DXA: Technical Aspects and Application.

This article is for educational purposes and is not a substitute for individualized medical evaluation. Body-fat distribution and body-composition results should be interpreted alongside medical history, metabolic laboratory testing, physical function, medications, hormones, nutrition, exercise, and other relevant clinical factors.